AFT upgrades guidance following maiden US sale

AFT upgrades guidance following maiden US sale
Managing director Hartley Atkinson says he's confident AFT's investments will reward shareholders over the medium to long term. (Image: Supplied)
John Anthony
Dual-listed pharmaceutical company AFT Pharmaceuticals has lifted its profit guidance for the year to March following the first sale of its intravenous pain-relief medicine in the United States.AFT expects operating profit to range between $23 million and $25m, up on earlier guidance of $22m to $24m.US successIn a statement to the Australian securities exchange (ASX) and New Zealand stock exchange (NZX) on Friday morning, AFT said the update followed a review of January trading and news that Hikma Pharmaceuticals, the US licensee of its pain-re...

More Markets

Listed retailers stand to gain from Trump tariffs:  Forsyth Barr
Retail

Listed retailers stand to gain from Trump tariffs: Forsyth Barr

Forsyth Barr lifted its KMD Brands target price by 10.4% after Trump tariff walkbacks.

NZ sharemarket rises as Trump backs down
Markets Market Close

NZ sharemarket rises as Trump backs down

The S&P/NZX 50 Index closed up 1.01% or 119.78 points.

Tom Raynel 23 Apr 2025
Transpower cautious over hydro lake level rule changes
Markets

Transpower cautious over hydro lake level rule changes

Transpower can authorise hydro lakes to dip further.

Ian Llewellyn 23 Apr 2025
Why this tech firm sees a Trump tariff opportunity
Markets The small cap wrap

Why this tech firm sees a Trump tariff opportunity

Plus IkeGPS' wins in the US, Trade Window targets trade war, TruScreen, and more.